D2ML guided prospective ROS1 potency and selectivity optimization
Assay-aware models were used to select 84 new compounds for synthesis and prospective testing in a ROS1 kinase program, with TRKB as an anti-target. The most selective prospective compound had a measured ROS1 IC50 of 14.7 nM and 233-fold selectivity over TRKB, compared with 20.3 nM and 79-fold for the most selective training-set compound. The evidence is biochemical and does not establish therapeutic efficacy or safety.
Technology: D2ML multi-stage deep neural networks trained across direct-to-biology assay data
Publication: Preprint · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Preprint
- Test type: direct test
- Tested: The authors prospectively synthesized and assayed 84 model-selected compounds. The most selective new compound had ROS1 IC50 14.7 nM and 233-fold selectivity over TRKB; the most selective training compound had 20.3 nM ROS1 IC50 and 79-fold selectivity.
- Still unknown: This is an in-vitro biochemical discovery result. It does not establish cellular activity, therapeutic efficacy, safety or clinical benefit. The paper compares a historical analog but makes no claim of global chemical novelty.
- AI role: Assay-aware models using data from multiple direct-to-biology screening stages selected compounds for prospective synthesis and ROS1/TRKB testing.
Evidence sources: https://arxiv.org/abs/2610.41070 · https://arxiv.org/html/2610.41070v1
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review date: 17 Nov 2026. Review scope: Primary arXiv v1 abstract, submission history and full text for date, affiliation, model methods and prospective assay result..
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.